Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4
The Breast Journal · 2023
DOI: 10.1155/2023/2875972 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Breast Journal, 2023. Verfasst von Meng Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School,…. Hauptthemen laut MEDLINE: Breast Neoplasms, MicroRNAs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Project on Maternal and Child Health Talents of Jiangsu Province.
Abstract (Originalsprache)
Tamoxifen is a drug used for treating breast cancer (BC), especially for individuals diagnosed with estrogen receptor-positive (ER+) BC. Its prolonged use could reduce the risk of recurrence and significantly lengthen the survival rate of BC patients. However, an increasing number of patients developed resistance to tamoxifen treatment, which reduced therapeutic efficiency and caused substandard prognosis. Therefore, the exploration of the molecular processes involved in tamoxifen resistance (TR) is urgently required. This investigation aimed to elucidate the relationship of microRNA-330 (miR-330-3p) with the TR of BC. There is little information on miR-330-3p′s link with drug-resistant BC, although it is well known to regulate cell proliferation and apoptosis. Primarily, miR-330-3p expression in parental BC (MCF7/T47D), TR (MCF7-TR), and T47D/TR cell lines was detected by qRT-PCR. Then, the impact of miR-330-3p on the TR of BC cells was assessed by a cell proliferation assay. Lastly, dual-luciferase reporter, qRT-PCR, and western blot assessments were carried out to identify histone deacetylase 4 (HDAC4) as the potential miR-330-3p target gene. The data indicated that miRNA-330 was overexpressed in TR ER+ BC cells and its overexpression could induce TR. Furthermore, miRNA-330 could also reduce the expression of HDAC4, which is closely linked to TR, and overexpression of HDAC4 could reverse miRNA-330-induced drug resistance. In summary, miR-330-3p could induce TR of ER+ BC cells by downregulating HDAC4 expression, which might be a novel marker of TR and a possible treatment target against BC patients who are tamoxifen-resistant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
- Department of Pathology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210001, China.
- Department of Ultrasound Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
- Department of Breast Disease Research Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China.
- Nanjing Maternal and Child Health Institute, Nanjing Maternal and Child Health Care Hospital, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing 210004, China.
ORCID-Profile: Meng Zhang, Jingjing Ma, Sheng Gao
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Project on Maternal and Child Health Talents of Jiangsu Province
- Nanjing Drum Tower Hospital
- Nanjing Medical Science and Technique Development Foundation
Zitieren
APA
Zhang, M., Wang, M., Jiang, Z., Fu, Z., Ma, J., & Gao, S. (2023). Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4. The Breast Journal. https://doi.org/10.1155/2023/2875972
Vancouver
Zhang M, Wang M, Jiang Z, Fu Z, Ma J, Gao S. Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4. The Breast Journal. 2023. doi:10.1155/2023/2875972
BibTeX
@article{Zhang2023,
author = {Zhang, Meng and Wang, Mei and Jiang, Zhiming and Fu, Ziyi and Ma, Jingjing and Gao, Sheng},
title = {Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4},
journal = {The Breast Journal},
year = {2023},
doi = {10.1155/2023/2875972}
}
EUVIMED